§ Federal grant opportunity · HT942526ORPCRA
DoW Orthopaedic, Clinical Research Award
Teresa M Parker-Reeser Grants Officer is accepting applications for DoW Orthopaedic, Clinical Research Award. The deadline is November 18, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Teresa M Parker-Reeser Grants Officer
- Application deadline
- November 18, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526ORPCRA
Program overview
Summary: The fiscal year 2026 (FY26) Orthopaedic Research Program (ORP) Clinical Research Award (CRA) seeks clinical research that evaluates orthopaedic-specific factors and interventions. The ORP intends for research supported by this mechanism to generate clinically useful evidence with potential to optimize patient outcomes and inform clinical care or policy. Applications must address how the proposed research will impact patient care and reduce the burden of orthopaedic injury and sequela. The ORP expects that research findings benefit Service Members, their families, Veterans and the general public. To meet the intent of the award mechanism, applications must specifically address at least one of the FY26 ORP CRA Focus Areas. Distinctive Features: · The CRA offers two research levels. Research Level 1 (RL1) supports clinical research in the following FY26 ORP focus areas: · Ligamentous Trauma · Osseointegration Outcomes · Return-to-Duty Strategies · Military Women’s Health Research Level 2 (RL2) supports clinical trials in the following FY26 ORP focus areas: · Ligamentous Trauma · Limb Stabilization and Protection · Return-to-Duty Strategies
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Teresa M Parker-Reeser Grants Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before November 18, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Rare Cancers Idea Development Award
- DoW Orthopaedic, Applied Research Award
- DoW Rare Cancers Resource and Community Development Award
- NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
- Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.